Identification of a Pharmacological Inducer of Lipoic Acid Synthase that Impacts Mitochondrial Function: Metabolic Benefits and Body Weight Loss without Changes in Caloric IntakePascale Fouqueray1*, Xavier Leverve (In Memoriam)2, Eric Fontaine2, Mathurin Baquié3, Claes Wollheim3, Harold Lebovitz4 and Sophie Bozec1
- Corresponding Author:
- Dr. Pascale Fouqueray
Poxel SA, 200 avenue Jean Jaurès, F-69007 Lyon, France
E-mail: [email protected]
Received Date: March 09, 2011; Accepted Date: May 13, 2011; Published Date: May 16, 2011
Citation: Fouqueray P, Leverve X, Fontaine E, Baquié M, Wollheim C, et al. (2011) Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. J Diabetes Metab 2:126. doi:10.4172/2155-6156.S11-002
Copyright: © 2011 Fouqueray P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the soriginal author and source are credited.
Objective: Lipoic Acid Synthase (LASY) was recently shown to play a critical role in inflammation, mitochondrial function and insulin resistance. In this study using a pharmacological inducer of LASY as a tool, we studied the effects of LASY induction in vivo in rodent models of obesity and type 2 diabetes.
Methods: We identified a small molecule that increases LASY mRNA and lipoic acid levels in vitro. Effect of the inducer (compound 1) on body weight, food intake, energy expenditure and metabolic parameters was studied in rodent models of genetic and diet-induced obesity.
Results: Compound 1 was identified as a transcriptional inducer of LASY. In vitro, compound 1 increased LASY mRNA expression, mitochondrial lipoic acid levels and improved mitochondrial function in cultured skeletal muscle cells. LASY mRNA and lipoic acid levels were significantly increased in skeletal muscle and adipose tissue of animals treated with compound 1. In genetic and diet-induced rodent models of obesity, treatment with compound 1 significantly reduced body weight gain and fat mass without changes in food intake. Whole-animal calorimetry revealed that compound 1-treated animals had a significant increase in energy expenditure over vehicle control. Compound 1 treatment was also accompanied by improvements in plasma metabolic parameters and increase in lean mass.
Conclusion: Our data suggests that the benefical effects of compound 1 are mediated by increase in mitochondrial lipoic acid levels, although general effects on mitochondrial function cannot be ruled out. These results establish the in vivo relevance of LASY induction and show the potential of a peripheral mediated approach for achieving many of the desired effects in treating obesity. Future studies focusing on the mechanism(s) by which compound 1 exerts its beneficial effects will help to reveal if these benefits are specific to LASY induction or are due to non-specific effects on mitochondrial function.